Last reviewed · How we verify
Current Domperidone
Current Domperidone acts as a dopamine D2 receptor antagonist.
Current Domperidone acts as a dopamine D2 receptor antagonist. Used for Gastroparesis.
At a glance
| Generic name | Current Domperidone |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | Dopamine antagonist |
| Target | Dopamine D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | Phase 2 |
Mechanism of action
By blocking dopamine D2 receptors, Current Domperidone reduces gastrointestinal motility and increases gastric emptying time, alleviating symptoms of gastroparesis and other gastrointestinal disorders.
Approved indications
- Gastroparesis
Common side effects
- Headache
- Dizziness
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Domperidone and Risk of Sudden Cardiac Death
- Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS) (PHASE2)
- EFFECT OF LOW LEVEL LASER THERAPY VERSUS ELECTROACUPUNCTURE ON POSTNATAL SCANTY MILK SECRETION (PHASE4)
- Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |